KMDA
Kamada Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$8.54
+3.26%Year over year
Reported trailing growth
- Revenue
- +13.2%
- EBITDA
- +22.7%
- EBIT
- +10.3%
- EPS
- +12.6%
- Free cash flow
- -16.2%
- Operating cash flow
- -10.2%
Forward estimates
Based on analyst estimates
- Revenue
- +9.6%
- EBITDA
- +24.9%
- EPS
- +29.9%
Three-year CAGR
- Revenue
- +11.7%
- EBITDA
- +53.7%
- EBIT
- +79.6%
- Net income
- +56.1%
- EPS
- +49.5%
- Free cash flow
- -11.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026